Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer

Chinese Journal of Medical Genetics

Volumn 24, Issue 1, 2007, Pages 31-34

  Liu, Feng ^a   Jiang, Bin ^a,b   Gong, Sheng Ji ^a   Yao, Bao Di ^a   Zhang, Wen Ying ^a   Zhu, Guan Shan ^c   Zhu, Zhong Zheng ^d   Gong, Yu Fang ^a   Wang, Mei Ling ^a   Hu, Xiao Hua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Shanghai GeneCore Biotechnologies Co Ltd   (China)

^d No 113 Hospital of People's Liberation Army   (China)

Author keywords

Epidermal growth factor receptor; Gene mutation; K RAS gene; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; K RAS PROTEIN;

ARTICLE; CANCER CONTROL; CHINESE; CLINICAL FEATURE; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33847308552     PISSN: 10039406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res, 2003, 284:31-53.
2. Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21:2237-2246.
3. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290:2149-2158.
4. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res, 2002, 62:5749-5754.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350:2129-2139.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304:1497-1500.
7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 2004, 101:13306-13311.
8. Suzuki Y, Orita M, Shiraishi M, et al. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene, 1990, 5:1037-1043.
9. Eberhard DA, Johnson BE, AmLer LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 2005, 23:1-13.
10. Shigematsu H, Lin L, Takahash T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 2005, 97:339-346.
11. Kim DW, Lu B, Hallahan DE. Receptor tyrosine kinase inhibitors as antiangiogenic agents. Curr Opin Investig Drugs, 2004, 5:597-604.
12. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol, 1999, 17:668-675.
13. Slebos RJ, Hruban RH, Dalesio O, et al. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst, 1991, 83:1024-1027.
14. Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer, 1996, 32A:2070-2074.
15. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350:2129-2139.